Swiss drug authority Swissmedic has begun evaluating the so-called “Covid-19 Vaccine AstraZeneca”. It is the first time that a drugmaker has presented a coronavirus vaccine for approval in Switzerland.
AstraZeneca, which developed the vaccine in collaboration with the University of Oxford, submitted its application to Swissmedic at the start of this month.
The vaccine’s scientific evaluation will be done via a “rolling submission” process. This allows a pharmaceutical company to launch the application procedure before a product’s development is complete.
This “enables Swissmedic to carry out the scientific assessment of non-clinical data from laboratory tests while clinical trials are still in progress,” announced Swissmedic in a statement on Tuesday, noting that trial results must be submitted for scientific review as they become available over the next weeks and months.
More
More
Half of Swiss would get vaccinated against Covid-19
This content was published on
If there were an efficient vaccination against coronavirus, every second person in Switzerland would take it, says a survey.
“However, no decision on authorisation can be taken until all the data needed to assess the safety, quality and efficacy of the vaccine have been submitted. The documentation must demonstrate how safe and effective the vaccine is in protecting humans against the new SARS-CoV-2 coronavirus,” wrote the Swiss drug authority.
Swissmedic noted that while it is reviewing the vaccine independently, it is also working closely with partner authorities abroad. No medicinal product can go onto the Swiss market without Swissmedic’s approval.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
Join the conversation!